[{"id":"17a373bf-e674-4aa0-a914-22e6aff84f1c","acronym":"CIRCALL","url":"https://clinicaltrials.gov/study/NCT07483476","created_at":"2026-03-28T01:37:46.104Z","updated_at":"2026-03-28T01:37:46.104Z","phase":"","brief_title":"Study of Cell-free DNA in Children and Adolescents With Acute Lymphoblastic Leukemia","source_id_and_acronym":"NCT07483476 - CIRCALL","lead_sponsor":"Assistance Publique - Hôpitaux de Paris","biomarkers":" ABL1 • KMT2A","pipe":" | ","alterations":" KMT2A rearrangement","tags":["ABL1 • KMT2A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KMT2A rearrangement"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 205","initiation":"Initiation: 04/01/2026","start_date":" 04/01/2026","primary_txt":" Primary completion: 07/01/2029","primary_completion_date":" 07/01/2029","study_txt":" Completion: 04/01/2034","study_completion_date":" 04/01/2034","last_update_posted":"2026-03-19"},{"id":"eaacbaad-f813-44b5-b98c-4ef8fd4a5156","acronym":"","url":"https://clinicaltrials.gov/study/NCT07480863","created_at":"2026-03-28T01:39:30.077Z","updated_at":"2026-03-28T01:39:30.077Z","phase":"Phase 2","brief_title":"Treatment of BTKi+Hi-CVP Regimen for Previously Untreated MZL","source_id_and_acronym":"NCT07480863","lead_sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","biomarkers":" CD20","pipe":" | ","alterations":" CD20 positive","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • vincristine • Inokai (orelabrutinib) • Anruixi (zuberitamab)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 65","initiation":"Initiation: 10/01/2025","start_date":" 10/01/2025","primary_txt":" Primary completion: 10/01/2029","primary_completion_date":" 10/01/2029","study_txt":" Completion: 10/02/2029","study_completion_date":" 10/02/2029","last_update_posted":"2026-03-18"},{"id":"a7c4f9e4-84af-4d2b-9a47-edc69ca3a38e","acronym":"","url":"https://clinicaltrials.gov/study/NCT07476729","created_at":"2026-03-28T01:40:41.936Z","updated_at":"2026-03-28T01:40:41.936Z","phase":"Phase 3","brief_title":"International Study for Treatment of Childhood Relapsed Precursor B-Cell ALL 2020 (IntReALL BCP 2020)","source_id_and_acronym":"NCT07476729","lead_sponsor":"Charite University, Berlin, Germany","biomarkers":" CD22","pipe":" | ","alterations":" CD19 positive • CD22 positive","tags":["CD22"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 positive • CD22 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Blincyto (blinatumomab) • Besponsa (inotuzumab ozogamicin)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 750","initiation":"Initiation: 04/01/2026","start_date":" 04/01/2026","primary_txt":" Primary completion: 03/31/2033","primary_completion_date":" 03/31/2033","study_txt":" Completion: 03/31/2033","study_completion_date":" 03/31/2033","last_update_posted":"2026-03-17"},{"id":"147008c9-b17e-4123-a459-475c325f46f7","acronym":"T-START-NR","url":"https://clinicaltrials.gov/study/NCT07470996","created_at":"2026-03-28T01:43:49.187Z","updated_at":"2026-03-28T01:43:49.187Z","phase":"","brief_title":"T Cell Lymphoma -Stratified Therapy After Response to First-line Treatment-NR","source_id_and_acronym":"NCT07470996 - T-START-NR","lead_sponsor":"Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine","biomarkers":" HLA-DRB1 • HLA-B • HLA-C","pipe":" | ","alterations":" ALK negative","tags":["HLA-DRB1 • HLA-B • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK negative"],"overall_status":"Recruiting","enrollment":" Enrollment 58","initiation":"Initiation: 10/01/2025","start_date":" 10/01/2025","primary_txt":" Primary completion: 05/30/2029","primary_completion_date":" 05/30/2029","study_txt":" Completion: 09/30/2029","study_completion_date":" 09/30/2029","last_update_posted":"2026-03-13"},{"id":"29314cf0-3dae-48bb-bacc-9547b377d15c","acronym":"","url":"https://clinicaltrials.gov/study/NCT07471789","created_at":"2026-03-28T01:43:57.744Z","updated_at":"2026-03-28T01:43:57.744Z","phase":"Phase 1/2","brief_title":"Safety and Efficacy of GYA01 (CART84) in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) and Acute Lymphoblastic T Leukemia Patients (T-ALL).","source_id_and_acronym":"NCT07471789","lead_sponsor":"Gyala Therapeutics","biomarkers":" CD8 • CD4","pipe":"","alterations":" ","tags":["CD8 • CD4"],"overall_status":"Recruiting","enrollment":" Enrollment 33","initiation":"Initiation: 02/04/2026","start_date":" 02/04/2026","primary_txt":" Primary completion: 05/31/2029","primary_completion_date":" 05/31/2029","study_txt":" Completion: 02/04/2031","study_completion_date":" 02/04/2031","last_update_posted":"2026-03-13"},{"id":"2f59ed54-b06e-4d43-9212-6877b8a1fbe8","acronym":"","url":"https://clinicaltrials.gov/study/NCT07470073","created_at":"2026-03-28T01:44:17.302Z","updated_at":"2026-03-28T01:44:17.302Z","phase":"Phase 1","brief_title":"A Clinical Study Exploring the Safety, Efficacy and Cell Metabolic Kinetics of Universal Car-t Cell Injection in CD19 and / or CD20 Positive Relapsed / Refractory B-cell Acute Lymphoblastic Leukemia in Adolescents, Children and Adults","source_id_and_acronym":"NCT07470073","lead_sponsor":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","biomarkers":" CD20","pipe":" | ","alterations":" CD20 positive","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 positive"],"overall_status":"Recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 04/01/2026","start_date":" 04/01/2026","primary_txt":" Primary completion: 12/31/2027","primary_completion_date":" 12/31/2027","study_txt":" Completion: 03/31/2028","study_completion_date":" 03/31/2028","last_update_posted":"2026-03-13"},{"id":"842583e2-8e92-49fc-94d6-2f73865d1b14","acronym":"","url":"https://clinicaltrials.gov/study/NCT07203352","created_at":"2025-10-04T08:00:11.817Z","updated_at":"2025-10-04T08:00:11.817Z","phase":"Phase 3","brief_title":"Efficacy of Targeted Drugs Combined With Chemotherapy in the Treatment of T-ALL","source_id_and_acronym":"NCT07203352","lead_sponsor":"Nanfang Hospital, Southern Medical University","biomarkers":" ABL2","pipe":"","alterations":" ","tags":["ABL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sorafenib"],"overall_status":"Recruiting","enrollment":" Enrollment 154","initiation":"Initiation: 10/01/2025","start_date":" 10/01/2025","primary_txt":" Primary completion: 12/01/2026","primary_completion_date":" 12/01/2026","study_txt":" Completion: 12/30/2026","study_completion_date":" 12/30/2026","last_update_posted":"2025-10-02"},{"id":"29889af3-ae43-4e06-bdfc-acec22c139fb","acronym":"","url":"https://clinicaltrials.gov/study/NCT07198867","created_at":"2025-10-04T08:02:56.736Z","updated_at":"2025-10-04T08:02:56.736Z","phase":"Phase 1","brief_title":"A Study of A-CAR028 Treatment in Subjects With Relapsed or Refractory Acute Myeloid Leukemia","source_id_and_acronym":"NCT07198867","lead_sponsor":"First Affiliated Hospital of Zhejiang University","biomarkers":" CD33","pipe":" | ","alterations":" CD33 positive","tags":["CD33"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD33 positive"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 09/30/2025","start_date":" 09/30/2025","primary_txt":" Primary completion: 12/30/2026","primary_completion_date":" 12/30/2026","study_txt":" Completion: 12/31/2027","study_completion_date":" 12/31/2027","last_update_posted":"2025-09-30"},{"id":"8551971c-dc39-40b0-a802-ab21b9ec4738","acronym":"","url":"https://clinicaltrials.gov/study/NCT07188740","created_at":"2025-09-27T08:44:07.719Z","updated_at":"2025-09-27T08:44:07.719Z","phase":"Phase 1","brief_title":"Metformin Inhibits DNMT3A Clonal Hematopoiesis in Acute Leukemia","source_id_and_acronym":"NCT07188740","lead_sponsor":"Institute of Hematology \u0026 Blood Diseases Hospital, China","biomarkers":" DNMT3A","pipe":"","alterations":" ","tags":["DNMT3A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e metformin"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 10/30/2025","start_date":" 10/30/2025","primary_txt":" Primary completion: 08/30/2027","primary_completion_date":" 08/30/2027","study_txt":" Completion: 08/30/2029","study_completion_date":" 08/30/2029","last_update_posted":"2025-09-23"},{"id":"1ab27b74-e0f4-4cec-8b70-3ecfc4fb824b","acronym":"Ven-BUCY","url":"https://clinicaltrials.gov/study/NCT07183878","created_at":"2025-09-27T08:46:54.624Z","updated_at":"2025-09-27T08:46:54.624Z","phase":"","brief_title":"Venetoclax-Enhanced BUCY vs. Standard BUCY Conditioning in High-Risk AML and MDS Patients Undergoing Allo-HSCT (Ven-BUCY Study)","source_id_and_acronym":"NCT07183878 - Ven-BUCY","lead_sponsor":"First Affiliated Hospital of Zhejiang University","biomarkers":" BCL2","pipe":"","alterations":" ","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • cyclophosphamide"],"overall_status":"Recruiting","enrollment":" Enrollment 138","initiation":"Initiation: 08/20/2025","start_date":" 08/20/2025","primary_txt":" Primary completion: 08/20/2027","primary_completion_date":" 08/20/2027","study_txt":" Completion: 08/20/2028","study_completion_date":" 08/20/2028","last_update_posted":"2025-09-19"},{"id":"a246864c-3497-4420-91ec-cca51a5f43a5","acronym":"CHARTHER","url":"https://clinicaltrials.gov/study/NCT07181785","created_at":"2025-09-20T07:04:37.321Z","updated_at":"2025-09-20T07:04:37.321Z","phase":"","brief_title":"Molecular Characterization and Outcomes of Aggressive B-Cell Lymphomas.","source_id_and_acronym":"NCT07181785 - CHARTHER","lead_sponsor":"Andrés José Maria Ferreri","biomarkers":" BCL2","pipe":"","alterations":" ","tags":["BCL2"],"overall_status":"Completed","enrollment":" Enrollment 555","initiation":"Initiation: 07/12/2022","start_date":" 07/12/2022","primary_txt":" Primary completion: 07/12/2023","primary_completion_date":" 07/12/2023","study_txt":" Completion: 07/12/2023","study_completion_date":" 07/12/2023","last_update_posted":"2025-09-18"},{"id":"5dbd5ae2-c64a-4324-a92e-acf2900c0634","acronym":"CHANCE","url":"https://clinicaltrials.gov/study/NCT07172204","created_at":"2025-09-20T07:07:45.699Z","updated_at":"2025-09-20T07:07:45.699Z","phase":"Phase 2","brief_title":"Alternating Regimen of VA and Low-dose CHA in the Treatment of Unfit Newly Diagnosed AML","source_id_and_acronym":"NCT07172204 - CHANCE","lead_sponsor":"First Affiliated Hospital of Zhejiang University","biomarkers":" BCL2","pipe":"","alterations":" ","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • cytarabine • azacitidine"],"overall_status":"Recruiting","enrollment":" Enrollment 25","initiation":"Initiation: 08/15/2025","start_date":" 08/15/2025","primary_txt":" Primary completion: 07/31/2027","primary_completion_date":" 07/31/2027","study_txt":" Completion: 07/31/2029","study_completion_date":" 07/31/2029","last_update_posted":"2025-09-15"},{"id":"b7618037-1369-4803-9a4d-36cc465a98d2","acronym":"","url":"https://clinicaltrials.gov/study/NCT07159906","created_at":"2025-09-13T08:44:39.729Z","updated_at":"2025-09-13T08:44:39.729Z","phase":"Phase 1/2","brief_title":"Homoharringtonine, BCL-2 Inhibitor, Rituximab, and Prednisone in Relapsed/Refractory Diffuse Large B-Cell Lymphoma","source_id_and_acronym":"NCT07159906","lead_sponsor":"First Affiliated Hospital of Zhejiang University","biomarkers":" BCL2","pipe":"","alterations":" ","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • prednisone • lisaftoclax (APG-2575) • Synribo (omacetaxine mepesuccinate)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 62","initiation":"Initiation: 09/08/2025","start_date":" 09/08/2025","primary_txt":" Primary completion: 08/01/2027","primary_completion_date":" 08/01/2027","study_txt":" Completion: 08/01/2028","study_completion_date":" 08/01/2028","last_update_posted":"2025-09-08"},{"id":"b6808cda-ab2a-4b3d-8cc3-0eab5b5b4415","acronym":"","url":"https://clinicaltrials.gov/study/NCT07157579","created_at":"2025-09-06T13:39:27.500Z","updated_at":"2025-09-06T13:39:27.500Z","phase":"","brief_title":"Notch 1 Mutation in Chronic Lymphocytic Leukemia and Non-Hodgkin's Lymphoma Patient","source_id_and_acronym":"NCT07157579","lead_sponsor":"Sohag University","biomarkers":" BCL2 • NOTCH1","pipe":"","alterations":" ","tags":["BCL2 • NOTCH1"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 80","initiation":"Initiation: 09/01/2025","start_date":" 09/01/2025","primary_txt":" Primary completion: 09/01/2027","primary_completion_date":" 09/01/2027","study_txt":" Completion: 09/01/2027","study_completion_date":" 09/01/2027","last_update_posted":"2025-09-05"},{"id":"f0b2108a-611c-4070-92fc-407c3cf54f4d","acronym":"SIGMA","url":"https://clinicaltrials.gov/study/NCT07151807","created_at":"2025-09-06T13:42:25.722Z","updated_at":"2025-09-06T13:42:25.722Z","phase":"","brief_title":"Serum IGF-1 and IGF-1Ec in Malignancy Assessment","source_id_and_acronym":"NCT07151807 - SIGMA","lead_sponsor":"Çanakkale Onsekiz Mart University","biomarkers":" IGF1","pipe":"","alterations":" ","tags":["IGF1"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 04/01/2025","start_date":" 04/01/2025","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2025-09-03"},{"id":"01306bab-0ded-4cdc-a0a1-544ea964a80a","acronym":"","url":"https://clinicaltrials.gov/study/NCT07147751","created_at":"2025-08-30T13:47:26.069Z","updated_at":"2025-08-30T13:47:26.069Z","phase":"","brief_title":"Characterization of Primary Central Nervous System Diffuse Large B Cell Lymphoma (PCNS-DLBCL) by Multiomic Approach","source_id_and_acronym":"NCT07147751","lead_sponsor":"International Extranodal Lymphoma Study Group (IELSG)","biomarkers":" BCL2","pipe":"","alterations":" ","tags":["BCL2"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 04/01/2026","start_date":" 04/01/2026","primary_txt":" Primary completion: 12/01/2029","primary_completion_date":" 12/01/2029","study_txt":" Completion: 12/01/2029","study_completion_date":" 12/01/2029","last_update_posted":"2025-08-29"},{"id":"327866a7-3b75-4b34-a977-d5d2009e3095","acronym":"GastricMALToma","url":"https://clinicaltrials.gov/study/NCT07144657","created_at":"2025-08-30T13:50:33.375Z","updated_at":"2025-08-30T13:50:33.375Z","phase":"Phase 2","brief_title":"Prospective Study of Frontline Antibiotics Therapy in the Treatment of Early-stage HP-negative Gastric MALT Lymphoma","source_id_and_acronym":"NCT07144657 - GastricMALToma","lead_sponsor":"National Taiwan University Hospital","biomarkers":" BCL2","pipe":"","alterations":" ","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 09/01/2025","start_date":" 09/01/2025","primary_txt":" Primary completion: 12/31/2029","primary_completion_date":" 12/31/2029","study_txt":" Completion: 12/31/2030","study_completion_date":" 12/31/2030","last_update_posted":"2025-08-27"},{"id":"23321d61-92f1-4817-9ef8-fa2c65366aec","acronym":"","url":"https://clinicaltrials.gov/study/NCT07134504","created_at":"2025-08-23T13:30:10.304Z","updated_at":"2025-08-23T13:30:10.304Z","phase":"","brief_title":"Primary Prostatic Lymphoma on a 66 Year-old Male in Mexico.","source_id_and_acronym":"NCT07134504","lead_sponsor":"Instituto Mexicano del Seguro Social","biomarkers":" BCL2","pipe":"","alterations":" ","tags":["BCL2"],"overall_status":"Completed","enrollment":" Enrollment 1","initiation":"Initiation: 07/20/2025","start_date":" 07/20/2025","primary_txt":" Primary completion: 07/30/2025","primary_completion_date":" 07/30/2025","study_txt":" Completion: 08/01/2025","study_completion_date":" 08/01/2025","last_update_posted":"2025-08-21"},{"id":"8ecfd71e-09dc-439f-af05-bbb7a6382e68","acronym":"","url":"https://clinicaltrials.gov/study/NCT07130695","created_at":"2025-08-23T13:32:09.751Z","updated_at":"2025-08-23T13:32:09.751Z","phase":"Phase 1","brief_title":"Olutasidenib Single Plus Combo Therapy in IDH1mut AML After Induction and Consolidation","source_id_and_acronym":"NCT07130695","lead_sponsor":"Virginia Commonwealth University","biomarkers":" IDH1","pipe":" | ","alterations":" IDH1 mutation","tags":["IDH1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rezlidhia (olutasidenib)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 15","initiation":"Initiation: 10/31/2025","start_date":" 10/31/2025","primary_txt":" Primary completion: 10/31/2027","primary_completion_date":" 10/31/2027","study_txt":" Completion: 10/31/2029","study_completion_date":" 10/31/2029","last_update_posted":"2025-08-19"},{"id":"d3130d99-194c-46a1-903b-9c16e7da7d5d","acronym":"LOOMIS","url":"https://clinicaltrials.gov/study/NCT03951220","created_at":"2025-08-23T13:30:42.676Z","updated_at":"2025-08-23T13:30:42.676Z","phase":"","brief_title":"The Development and Pilot Testing of a New MR Imaging Protocol to Quantify Myeloma Disease Burden and Bone Loss","source_id_and_acronym":"NCT03951220 - LOOMIS","lead_sponsor":"Oxford University Hospitals NHS Trust","biomarkers":" DKK1","pipe":"","alterations":" ","tags":["DKK1"],"overall_status":"Completed","enrollment":" Enrollment 67","initiation":"Initiation: 03/29/2018","start_date":" 03/29/2018","primary_txt":" Primary completion: 12/30/2020","primary_completion_date":" 12/30/2020","study_txt":" Completion: 12/30/2020","study_completion_date":" 12/30/2020","last_update_posted":"2025-08-19"},{"id":"60175a3a-039d-4fa5-932d-b2536bc3f475","acronym":"","url":"https://clinicaltrials.gov/study/NCT07117305","created_at":"2025-08-16T14:06:42.122Z","updated_at":"2025-08-16T14:06:42.122Z","phase":"Phase 1/2","brief_title":"CD7 CAR-T Combined With Autologous Hematopoietic Stem Cell Transplantation","source_id_and_acronym":"NCT07117305","lead_sponsor":"Zhengzhou University","biomarkers":" CD7","pipe":"","alterations":" ","tags":["CD7"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 38","initiation":"Initiation: 09/01/2025","start_date":" 09/01/2025","primary_txt":" Primary completion: 09/30/2027","primary_completion_date":" 09/30/2027","study_txt":" Completion: 12/01/2027","study_completion_date":" 12/01/2027","last_update_posted":"2025-08-12"},{"id":"cbd75b78-349b-4631-8a47-5cdf0f95df72","acronym":"","url":"https://clinicaltrials.gov/study/NCT07113132","created_at":"2025-08-09T14:21:21.716Z","updated_at":"2025-08-09T14:21:21.716Z","phase":"","brief_title":"Role of SF3B1 Mutation in Assessment of Acute and Chronic Lymphatic Leukemia","source_id_and_acronym":"NCT07113132","lead_sponsor":"Safaa Ali","biomarkers":" SF3B1","pipe":"","alterations":" ","tags":["SF3B1"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 84","initiation":"Initiation: 08/01/2025","start_date":" 08/01/2025","primary_txt":" Primary completion: 07/01/2026","primary_completion_date":" 07/01/2026","study_txt":" Completion: 07/01/2027","study_completion_date":" 07/01/2027","last_update_posted":"2025-08-08"},{"id":"4bb42519-747d-45f0-98ad-774255094bb0","acronym":"","url":"https://clinicaltrials.gov/study/NCT07109518","created_at":"2025-08-09T14:25:49.588Z","updated_at":"2025-08-09T14:25:49.588Z","phase":"Phase 1","brief_title":"uCD7 CART for Relapsed or Refractory CD7 Positive Hematologic Malignancies","source_id_and_acronym":"NCT07109518","lead_sponsor":"Institute of Hematology \u0026 Blood Diseases Hospital, China","biomarkers":" CD7","pipe":"","alterations":" ","tags":["CD7"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • cyclophosphamide • fludarabine IV"],"overall_status":"Recruiting","enrollment":" Enrollment 12","initiation":"Initiation: 06/28/2025","start_date":" 06/28/2025","primary_txt":" Primary completion: 06/28/2028","primary_completion_date":" 06/28/2028","study_txt":" Completion: 06/28/2030","study_completion_date":" 06/28/2030","last_update_posted":"2025-08-07"},{"id":"7a9b9cc2-6f03-4498-b926-18b38cfd8aef","acronym":"","url":"https://clinicaltrials.gov/study/NCT07106723","created_at":"2025-08-09T14:48:30.931Z","updated_at":"2025-08-09T14:48:30.931Z","phase":"Phase 2","brief_title":"Clinical Study of the Safety and Efficacy of ASCT Combined With CD7-CART in the Treatment of CD7+ TCL","source_id_and_acronym":"NCT07106723","lead_sponsor":"Institute of Hematology \u0026 Blood Diseases Hospital, China","biomarkers":" CD7","pipe":"","alterations":" ","tags":["CD7"],"overall_status":"Recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 06/01/2025","start_date":" 06/01/2025","primary_txt":" Primary completion: 01/07/2029","primary_completion_date":" 01/07/2029","study_txt":" Completion: 01/07/2030","study_completion_date":" 01/07/2030","last_update_posted":"2025-08-06"}]